Intravitreal plasmin effectively treats DME patients unresponsive to other treatments

December 2008
Ocular Surgery News Europe/Asia-Pacific Edition;Dec2008, Vol. 19 Issue 12, p1
The article reports on the efficacy of intravitreal plasmin for the treatment of diabetic macular edema (DME) that were unresponsive to laser or other injections. Findings of research on the effectiveness of intravitreal plasmin injections were presented by Patricia Udaondo at the 2008 American Academy of Ophthalmology meeting. She explained that intravitreal injection of autologous plasmin effectively reduces macular thickening due to diabetic macular edema and improves visual acuity.


Related Articles

  • Intravitreal enzyme may improve BRVO. Hasson, Matt; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p9 

    The article discusses a study which found that autologous plasmin enzyme intravitreal injection may reduce macular edema and improve visual acuity in people with branch retinal vein occlusion (BRVO).

  • Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema. Elsawy, Moataz F. // Clinical Ophthalmology;2012 Part 2, Vol. 6, p2063 

    Objectives: To evaluate the outcome of vitreolysis using intravitreal autologous plasmin (IAP) injection as a sole therapeutic modality for patients with diffuse diabetic macular edema in comparison to triamcinolone acetonide (TA). Patients and methods: The study included 50 diabetic patients,...

  • Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). Sivaprasad, Sobha; Crosby-Nwaobi, Roxanne; Ling Zhi Heng; Peto, Tunde; Michaelides, Michel; Hykin, Phil // British Journal of Ophthalmology;Sep2013, Vol. 97 Issue 9, p1177 

    Aims To explore the parameters that influence injection frequency in patients treated with intravitreal bevacizumab (ivB) for diabetic macular oedema. Injection frequency was considered as a surrogate marker of persistent or recurrent oedema. Methods A post hoc analysis of the patients...

  • Intravitreal Triamcinolone in Diabetic Retinopathy. Abraldes, Maximino J.; Fernández, Maribel; Gómez-Ulla, Francisco // Current Diabetes Reviews;2009, Vol. 5 Issue 1, p18 

    Diabetic macular edema is an important cause of visual loss in the developed world and may frequently lead to irreversible changes in visual acuity. The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular...

  • Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema. Inagaki, Keiji; Ohkoshi, Kishiko; Ohde, Sachiko; Deshpande, Gautam; Ebihara, Nobuyuki; Murakami, Akira // Japanese Journal of Ophthalmology;Jan2015, Vol. 59 Issue 1, p21 

    Purpose: To compare the efficacy of 577- and 810-nm subthreshold micropulse laser photocoagulation (SMLP) combined with direct photocoagulation to microaneurysms in diabetic macular edema (DME). Methods: A prospective nonrandomized interventional case series. Forty-nine consecutive patients (53...

  • Anti-VEGF may improve visual acuity, reduce macular edema in patients with CRVO.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p12 

    The article reports a study which showed that patients treated with 1.25 mg intravitreal bevacizumab injection for central retinal vein occlusion, showed a significant increase in visual acuity.

  • Reduced visual acuity following standard ETDRS macular laser for clinically significant macular oedema. Richardson, E C; Patel, J; Hykin, P G // Eye;Apr2003, Vol. 17 Issue 3, p431 

    Eye (2003) 17, 431-433. doi:10.1038/sj.eye.6700337

  • Oxygen Therapy May Improve Vision Worsened by Diabetes.  // Ascribe Newswire: Medicine;5/19/2004, p151 

    Oxygen delivered through the nose may improve poor vision caused by diabetic macular edema, fluid buildup in the part of the eye responsible for central vision, according to a pilot study by scientists at Johns Hopkins and the National Eye Institute. In a study of five diabetic patients with...

  • Bevacizumab.  // Reactions Weekly;3/14/2009, Issue 1243, p11 

    The article describes the case of a 58-year-old woman who experienced acute visual acuity (VA) loss after intravitreal bevacizumab for chronic diabetic macular oedema. The medical history of the woman was notable for nonproliferative diabetic retinopathy and she had undergone focal laser...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics